2023
DOI: 10.1016/j.transci.2023.103706
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 38 publications
0
3
0
Order By: Relevance
“…First-line treatment of autoimmune TTP includes prompt initiation of therapeutic plasma exchange (TPE), steroids, and rituximab. A newer agent, caplacizumab, is now approved for use in conjunction with TPE for treatment of TTP [38,39].…”
Section: 33mentioning
confidence: 99%
“…First-line treatment of autoimmune TTP includes prompt initiation of therapeutic plasma exchange (TPE), steroids, and rituximab. A newer agent, caplacizumab, is now approved for use in conjunction with TPE for treatment of TTP [38,39].…”
Section: 33mentioning
confidence: 99%
“…Instead, TPE can be conducted with an accepted media, such as albumin, and supplementation of deficient ADAMTS13 accomplished using ADAMTS13‐enriched plasma fractions, provided they are acceptable to the individual patient. Reported fractions utilized in this circumstance include cryoprecipitate, cryo‐poor plasma, Koate‐DVI, and Alphanate 52 …”
Section: Evolving Landscape Of Therapeutic Apheresis and Cellular The...mentioning
confidence: 99%
“…To reduce inhibitor levels, hasten remission, and prevent relapse, rituximab (Genentech, South San Francisco, CA) has entered standard practice for management of TTP 52 . More recently, caplacizumab (Genzyme, Cambridge MA, USA), an anti‐VWF humanized single‐variable‐domain immunoglobulin available for management of iTTP, 53–55 received FDA approval in December of 2019 for the treatment of iTTP in conjunction with TPE.…”
Section: Evolving Landscape Of Therapeutic Apheresis and Cellular The...mentioning
confidence: 99%